中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
10期
27-31
,共5页
周建平%沈玉霞%殷葵%王琛%仇玉臣%王万相%邓建今
週建平%瀋玉霞%慇葵%王琛%仇玉臣%王萬相%鄧建今
주건평%침옥하%은규%왕침%구옥신%왕만상%산건금
脑血管意外%血小板活化%1-烷基-2-乙酰甘油磷酸胆碱酯酶%基因多态性
腦血管意外%血小闆活化%1-烷基-2-乙酰甘油燐痠膽堿酯酶%基因多態性
뇌혈관의외%혈소판활화%1-완기-2-을선감유린산담감지매%기인다태성
Cerebrovascular anident%Platelet activation%1-Alkyl-2-acetylglycerophospho-choline esterase%Gene polymorphism
目的 探讨血小板活化因子乙酰水解酶(PAF-AH)基因多态性与缺血性脑卒中的关系.方法 应用PCR技术,分析205例缺血性脑卒中患者(脑卒中组)及114例健康体检者(对照组)的基因型.并测定血浆血小板活化因子(PAF)、α颗粒膜糖蛋白140(GMP-140)、β-血小板球蛋白(β-TG)和血小板第4因子(PF4)水平.结果 脑卒中组PAF-AH.基因突变率和血浆PAF、GMP-140、β-TG和PF4水平[分别为42.44%、(91.08±39.10)ng/L、(36.46±13.10)μg/L、(41.75±11.18)μg/L、(29.05±9.16)μg/L]均显著高于对照组[分别为21.05%、(64.30±18.81)ng/L、(18.27±7.68)μg/L、(30.94±8.47)μg/L、(18.75±6.06)μg/L](P<0.01)脑卒中组基因突变者血浆PAF、GMP-140水平显著高于无基因突变者(P<0.01)结论 缺血性脑卒中患者急性期血小板活化增强,且与PAF-AH基因多态性相关.PAF-AH基因突变可能是缺血性脑卒中的一种遗传危险标志.
目的 探討血小闆活化因子乙酰水解酶(PAF-AH)基因多態性與缺血性腦卒中的關繫.方法 應用PCR技術,分析205例缺血性腦卒中患者(腦卒中組)及114例健康體檢者(對照組)的基因型.併測定血漿血小闆活化因子(PAF)、α顆粒膜糖蛋白140(GMP-140)、β-血小闆毬蛋白(β-TG)和血小闆第4因子(PF4)水平.結果 腦卒中組PAF-AH.基因突變率和血漿PAF、GMP-140、β-TG和PF4水平[分彆為42.44%、(91.08±39.10)ng/L、(36.46±13.10)μg/L、(41.75±11.18)μg/L、(29.05±9.16)μg/L]均顯著高于對照組[分彆為21.05%、(64.30±18.81)ng/L、(18.27±7.68)μg/L、(30.94±8.47)μg/L、(18.75±6.06)μg/L](P<0.01)腦卒中組基因突變者血漿PAF、GMP-140水平顯著高于無基因突變者(P<0.01)結論 缺血性腦卒中患者急性期血小闆活化增彊,且與PAF-AH基因多態性相關.PAF-AH基因突變可能是缺血性腦卒中的一種遺傳危險標誌.
목적 탐토혈소판활화인자을선수해매(PAF-AH)기인다태성여결혈성뇌졸중적관계.방법 응용PCR기술,분석205례결혈성뇌졸중환자(뇌졸중조)급114례건강체검자(대조조)적기인형.병측정혈장혈소판활화인자(PAF)、α과립막당단백140(GMP-140)、β-혈소판구단백(β-TG)화혈소판제4인자(PF4)수평.결과 뇌졸중조PAF-AH.기인돌변솔화혈장PAF、GMP-140、β-TG화PF4수평[분별위42.44%、(91.08±39.10)ng/L、(36.46±13.10)μg/L、(41.75±11.18)μg/L、(29.05±9.16)μg/L]균현저고우대조조[분별위21.05%、(64.30±18.81)ng/L、(18.27±7.68)μg/L、(30.94±8.47)μg/L、(18.75±6.06)μg/L](P<0.01)뇌졸중조기인돌변자혈장PAF、GMP-140수평현저고우무기인돌변자(P<0.01)결론 결혈성뇌졸중환자급성기혈소판활화증강,차여PAF-AH기인다태성상관.PAF-AH기인돌변가능시결혈성뇌졸중적일충유전위험표지.
Objective To investigate the corelation between platelet activating factor acetylhydrolase (PAF-AH) genetic polymorphism and ischemic stroke. Methods The plasma PAF-AH genotype was determined in 205 patients with iachemic stroke and 114 normal subjects by the polymerase chain reaction. The levels of plasma platelet activating factor (PAF), platelet α-granule membrane glycoprotein-140(GMP-140), β-thromboglobulin (β-TG) and the levels of platelet factor 4 (PF4) were analyzed. Results The prevalence of the mutation genotype and plasma PAF, GMP-140, β-TG and PF4 in the patients with isehemic stroke [42.44%,(91.08 ± 39.10) ng/L, (36.46 ± 13.10) μg/L, (41.75 ± 11.18) μg/L, (29.05 ± 9.16) g/L, respectively] were significantly higher than those in the controls[21.05%,(64.30 ± 18.81) ng/L, (18.27 ± 7.68) μg/L, (30.94 ± 8.47) μg/L, (18.75 ± 6.06) μg/L](P< 0.01). The levels of plasma PAF, GMP-140 were significantly higher in mutation genotype patients than those in the normal genotype patients (P < 0.01). Conclusions The activation function of platelet in the acute phase of patients with ischemic stroke increases, and it is associated with genetic polymorphism of PAF-AH. The PAF-AH gene mutation may be a novel genetic marker for high risk of ischemic stroke.
